23 reports of this reaction
2.1% of all MEXILETINE HYDROCHLORIDE reports
#6 most reported adverse reaction
IMPAIRED WORK ABILITY is the #6 most commonly reported adverse reaction for MEXILETINE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 23 FDA adverse event reports linking MEXILETINE HYDROCHLORIDE to IMPAIRED WORK ABILITY. This represents approximately 2.1% of all 1,120 adverse event reports for this drug.
Patients taking MEXILETINE HYDROCHLORIDE who experience impaired work ability should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
IMPAIRED WORK ABILITY is a less commonly reported adverse event for MEXILETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to impaired work ability, the following adverse reactions have been reported for MEXILETINE HYDROCHLORIDE:
The following drugs have also been linked to impaired work ability in FDA adverse event reports:
IMPAIRED WORK ABILITY has been reported as an adverse event in 23 FDA reports for MEXILETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
IMPAIRED WORK ABILITY accounts for approximately 2.1% of all adverse event reports for MEXILETINE HYDROCHLORIDE, making it a notable side effect.
If you experience impaired work ability while taking MEXILETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.